Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 1077-1081

  Djunic, Irena ^a   Virijevic, Marijana ^a   Novkovic, Aleksandra ^a   Djurasinovic, Vladislava ^a   Colovic, Natasa ^a   Vidovic, Ana ^a   Suvajdzic Vukovic, Nada ^a   Tomin, Dragica ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Acute myeloid leukemia; Chemotherapy; Comorbidity; Elderly patients; Overall survival

Indexed keywords

CYTARABINE; DAUNORUBICIN; LACTATE DEHYDROGENASE; MITOXANTRONE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER REGRESSION; COMORBIDITY; CONTINUOUS INFUSION; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPHENOTYPING; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; CLINICAL TRIAL; DECISION MAKING; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; REMISSION; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; DECISION MAKING; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84866305328     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9853-8     Document Type: Article

References (18)

1. Hiddeman W, Kern W, Schoch C, Fonatsch C, Heinecke A, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999;17:3569-76.
2. Stone RM. The difficult problem of acute myeloid leukemia in older adult. CA Cancer J Clin. 2002;52:363-71.
3. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481-5.
4. Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high risk myelodisplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106: 1090-8.
5. Malfuson JV, Etienne A, Turlure P, de Revel T, Tomas X, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica. 2008;93: 1806-13.
6. Rowe JM. Treatment of acute myeloid leukemia in older adults. Leukemia. 2000;14:480-7.
7. Estey EH. How I treat older patients with AML. Blood. 2004;96: 1670-3.
8. Farag SS, Archer KJ, Mrozek K, Ruppert AS, Carroll AJ, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years age or older with acute myeloid leukemia: results from cancer and leukemia group B 8461. Cancer and leukemia group B 8461. Blood. 2006;108:63-73.
9. Etienne A, Esterni B, Charbonnier A, Mozziconacci MJ, Arnoulet C, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer. 2007;109:1376-83.
10. Breccia M, Frustaci AM, Cannella L, Stefanizzi C, Latagliata R, et al. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukemia patients. Haem Oncol. 2009;27:148-53.
11. Sorror ML, Marris MB, Storb R, Baron F, Sandmaier BM, et al. Hematopoetic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogenic HCT. Blood. 2005;106:2912-9.
12. Feinstein AR. The pretherapeutic classification of co-morbidity in chronic disease. J Clin Dis. 1970;23:455-68.
13. Birim O, Kappetein AP, Bogers AJJC. Charlson comorbidity index as a predictor of long term outcome after surgery for nonsmall cell lung cancer. Eur J Cargiothorac Surg. 2005;28:759-62.
14. Cheson BD, Bennet JM, Kopecky KJ, Buchner T, Willman CL, et al. International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcome, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642-9.
15. Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:219-28.
16. Donner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood. 2010;115:454-74.
17. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, et al. The haematopoetic cell transplantation comorbidity index score predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukemia. Br J Haematol. 2007;136:624-7.
18. Klepin HD, Baldalucci L. Acute myelogenous leukemia in older adults. Onncologist. 2009;14:222-32.